Overview

The Safety and Efficiency of Luspatercept in Chinese Adults With Transfusion Dependent β-thalassemia: a Real-world Study

Status:
Recruiting
Trial end date:
2023-04-30
Target enrollment:
Participant gender:
Summary
This is a prospective, single-arm, open-label study. Twenty adult patients with transfusion-dependent β -thalassemia will be enrolled to receive Luspatercept with optimal supportive care, including blood transfusion and iron removal, based on the clinician's judgment and practice. The main objective of this study was to evaluate the efficacy and safety of Luspatercept in the treatment of adult patients with transfusion-dependent β -thalassaemia in Chinese clinical practice, and to provide evidence reference for subsequent clinical use.
Phase:
Phase 4
Details
Lead Sponsor:
Sun Yat-sen University
Treatments:
Immunoglobulin Fc Fragments
Luspatercept